A Phase Ib, Randomized, Double-Blind, Placebo Controlled Study to Determine the Safety, Tolerance, Pharmacokinetic and Pharmacodynamic Effects of Single Doses of Larazotide Acetate (AT-1001) in Celiac Disease Subjects.
Latest Information Update: 06 Nov 2021
At a glance
- Drugs Larazotide (Primary)
- Indications Coeliac disease
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Alba Therapeutics
Most Recent Events
- 12 Dec 2014 New trial record